Your browser doesn't support javascript.
loading
Comparison of Gout Flares With the Initiation of Treat-to-Target Allopurinol and Febuxostat: A Post-Hoc Analysis of a Randomized Multicenter Trial.
Barry, Austin; Helget, Lindsay N; Androsenko, Maria; Wu, Hongsheng; Kramer, Bridget; Newcomb, Jeff A; Brophy, Mary T; Davis-Karim, Anne; England, Bryant R; Ferguson, Ryan; Pillinger, Michael H; Neogi, Tuhina; Palevsky, Paul M; Merriman, Tony R; O'Dell, James R; Mikuls, Ted R.
Afiliación
  • Barry A; Veterans Affairs (VA) Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, Nebraska.
  • Helget LN; Veterans Affairs (VA) Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, Nebraska.
  • Androsenko M; VA Boston Cooperative Studies Program Coordinating Center, Boston, Massachusetts.
  • Wu H; VA Boston Cooperative Studies Program Coordinating Center, Boston, Massachusetts, and Babson College, Wellesley, Massachusetts.
  • Kramer B; Veterans Affairs (VA) Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, Nebraska.
  • Newcomb JA; Veterans Affairs (VA) Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, Nebraska.
  • Brophy MT; VA Boston Cooperative Studies Program Coordinating Center and VA Boston Health Care System, Boston University, Boston, Massachusetts.
  • Davis-Karim A; VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, New, Mexico.
  • England BR; Veterans Affairs (VA) Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, Nebraska.
  • Ferguson R; VA Boston Cooperative Studies Program Coordinating Center and Boston University School of Medicine, Boston, Massachusetts.
  • Pillinger MH; VA New York Harbor Health Care System and New York University Grossman School of Medicine, New York, New York.
  • Neogi T; Boston University School of Medicine, Boston, Massachusetts.
  • Palevsky PM; VA Pittsburgh Health Care System and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
  • Merriman TR; University of Alabama at Birmingham.
  • O'Dell JR; Veterans Affairs (VA) Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, Nebraska.
  • Mikuls TR; Veterans Affairs (VA) Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, Nebraska.
Arthritis Rheumatol ; 76(10): 1552-1559, 2024 Oct.
Article en En | MEDLINE | ID: mdl-38925627
ABSTRACT

OBJECTIVE:

Initiating urate-lowering therapy (ULT) in gout can precipitate arthritis flares. There have been limited comparisons of flare risk during the initiation and escalation of allopurinol and febuxostat, administered as a treat-to-target strategy with optimal anti-inflammatory prophylaxis.

METHODS:

This was a post-hoc analysis of a 72-week randomized, double-blind, placebo-controlled, noninferiority trial comparing the efficacy of allopurinol and febuxostat. For this analysis, the occurrence of flares was examined during weeks 0 to 24 when ULT was initiated and titrated to a serum urate (sUA) goal of less than 6 mg/dl (<5 mg/dl if tophi). Flares were assessed at regular intervals through structured participant interviews. Predictors of flare, including treatment assignment, were examined using multivariable Cox proportional hazards regression.

RESULTS:

Study participants (n = 940) were predominantly male (98.4%) and had a mean age of 62.1 years with approximately equal proportions receiving allopurinol or febuxostat. Mean baseline sUA was 8.5 mg/dl and all participants received anti-inflammatory prophylaxis (90% colchicine). In a multivariable model, there were no significant associations of ULT treatment (hazard ratio [HR] 1.17; febuxostat vs allopurinol), ULT-dose escalation (HR 1.18 vs no escalation), prophylaxis type, or individual comorbidity with flare and no evidence of ULT-dose escalation interaction. Factors independently associated with flare risk during ULT initiation/escalation included younger age, higher baseline sUA, and absence of tophi.

CONCLUSION:

These results demonstrate that gout flare risk during the initiation and titration of allopurinol is similar to febuxostat when these agents are administered according to a treat-to-target strategy using gradual ULT-dose titration and best practice gout flare prophylaxis.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Alopurinol / Supresores de la Gota / Brote de los Síntomas / Febuxostat / Gota Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Arthritis Rheumatol Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Alopurinol / Supresores de la Gota / Brote de los Síntomas / Febuxostat / Gota Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Arthritis Rheumatol Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos